Aditxt Therapeutics develops nucleic acid-based therapies aimed at restoring immune tolerance to treat chronic diseases. Their approach targets the underlying mechanisms of immune dysfunction, providing long-lasting treatment options for patients with severe conditions.
Funding
$1.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic diseases stem from immune system dysfunction, where the body attacks its own tissues or fails to respond adequately to external threats. Current treatments often manage symptoms without addressing the underlying cause of immune dysfunction, leading to limited long-term efficacy and potential side effects.
Solution
Aditxt Therapeutics is developing nucleic acid-based therapies designed to restore immune tolerance and provide long-lasting treatment for chronic diseases. Their approach focuses on modulating the immune system to address the root causes of immune dysfunction, rather than merely treating the symptoms. Aditxt operates through several subsidiaries, including Adimune, which focuses on restoring immune tolerance, Pearsanta, which develops personalized diagnostic and monitoring solutions, and Adivir, which is dedicated to developing medicines, diagnostics, and vaccines for public health threats. The company's innovations are supported by teams of clinical researchers, chemists, computer scientists, and biostatisticians.
Target Audience
The primary target audience includes individuals suffering from chronic diseases, healthcare providers seeking advanced diagnostic tools, and public health organizations addressing infectious disease threats.
Features
- Adimune: Developing medications to restore immune tolerance for chronic diseases.
- Pearsanta: Creating personalized, data-driven diagnostic and monitoring solutions for optimal health and wellness, including biosample collection and processing.
- Adivir: Developing medicines, diagnostics, and vaccines for public health threats, emerging infectious diseases, and immunotherapies.
- AditxtScore: Technology for monitoring the immune system.
- CaSe Platform: Adductomics-based platform for early cancer detection acquired by Pearsanta.